Dynavax Technologies (NASDAQ:DVAX) Releases Quarterly Earnings Results, Meets Estimates

Dynavax Technologies (NASDAQ:DVAX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05, Zacks reports. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%.

Dynavax Technologies Trading Up 1.9 %

NASDAQ DVAX traded up $0.25 during mid-day trading on Thursday, hitting $13.34. The company’s stock had a trading volume of 1,866,594 shares, compared to its average volume of 1,802,517. The firm has a market capitalization of $1.75 billion, a P/E ratio of 102.58 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $13.89. The stock’s fifty day simple moving average is $12.80 and its two-hundred day simple moving average is $11.98.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, HC Wainwright upped their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.